Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P00374
UPID:
DYR_HUMAN
Alternative names:
-
Alternative UPACC:
P00374; B4DDD2; Q14130; Q6IRW8
Background:
Dihydrofolate reductase plays a pivotal role in folate metabolism, essential for DNA synthesis and repair. It catalyzes the reduction of dihydrofolate to tetrahydrofolate, aiding in the synthesis of purines, thymidylate, and amino acids.
Therapeutic significance:
Megaloblastic anemia due to dihydrofolate reductase deficiency showcases the critical role of this enzyme in human health. Targeting dihydrofolate reductase offers a pathway to address severe metabolic disorders, highlighting its potential in therapeutic interventions.